Bicycle Therapeutics (NASDAQ:BCYC) Given New $36.00 Price Target at Oppenheimer

Bicycle Therapeutics (NASDAQ:BCYC) had its price objective trimmed by Oppenheimer from $44.00 to $36.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities research analysts have also issued reports about the company. Truist Financial set a $8.00 price objective on Bicycle Therapeutics in a research report on Tuesday. Morgan Stanley reaffirmed a “sell” rating and issued a $13.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Needham & Company LLC reduced their price objective on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Citizens Jmp decreased their price objective on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $14.50.

Bicycle Therapeutics Stock Down 7.3%

Bicycle Therapeutics stock opened at $4.70 on Wednesday. The company has a market capitalization of $326.04 million, a PE ratio of -1.49 and a beta of 1.65. The firm has a fifty day simple moving average of $5.87 and a two-hundred day simple moving average of $6.79. Bicycle Therapeutics has a twelve month low of $4.59 and a twelve month high of $9.94.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.71. Bicycle Therapeutics had a negative return on equity of 32.40% and a negative net margin of 301.66%.The firm had revenue of $47.96 million during the quarter, compared to the consensus estimate of $7.08 million. As a group, equities analysts expect that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares in the company, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares of the company’s stock, valued at $565,155.69. This represents a 4.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 38,029 shares of company stock valued at $251,966. 22.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Assetmark Inc. lifted its position in Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after acquiring an additional 1,552 shares during the period. Clearstead Advisors LLC grew its holdings in Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares during the period. Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Bicycle Therapeutics during the fourth quarter valued at approximately $71,000. Ausdal Financial Partners Inc. bought a new position in shares of Bicycle Therapeutics during the second quarter valued at approximately $70,000. Finally, Vontobel Holding Ltd. purchased a new position in shares of Bicycle Therapeutics during the fourth quarter valued at approximately $71,000. 86.15% of the stock is currently owned by institutional investors.

Key Bicycle Therapeutics News

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Q4 results materially beat expectations — Bicycle reported EPS of ($0.29) vs. consensus ($1.00) and revenue of $47.95M vs. $7.08M, a large topline surprise that supports the company’s commercial progress and clinical outlook. Read More.
• Neutral Sentiment: Short‑interest reports show a “large increase” flagged for March but list zero shares and NaN changes; the short‑interest ratio is reported as 0.0 days — this appears to be a reporting/data anomaly and is unlikely to be a meaningful driver while figures remain inconsistent.
• Negative Sentiment: Oppenheimer cut its price target from $44 to $36 but kept an “outperform” rating — a notable reduction in upside that can weigh on sentiment. Read More.
• Negative Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and moved to “sector perform” — another downward revision that reduces analyst‑implied valuation. Read More.
• Negative Sentiment: Citizens Jmp trimmed its target from $12 to $8 while maintaining “market outperform” — a cut that may temper near‑term enthusiasm. Read More.
• Negative Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating — another sizable reduction in analyst upside that could pressure the stock despite the buy rating. Read More.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.